Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
02/26/2021 - 02:00 AM
NEW YORK and LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that an interview with its CEO, Dr Kunwar Shailubhai, will air on The RedChip Money Report on Bloomberg Television on Saturday, February 27, 2021 at 7 p.m. local time across the United States and on the Bloomberg Network in Europe on Sunday, February 28, 2021 at 6 p.m. local time. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in 73M homes and on the Bloomberg Network in Europe in 100M homes at 6 p.m. local time on Sundays.
In the exclusive interview, Dr Shailubhai discusses topline data from Tiziana’s COVID-19 trial, its multiple Phase 2 trial launches expected in 2021, and the potential application of Foralumab in a wide range of autoimmune and inflammatory diseases.
“The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc (TLSA)
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
U.S. Investor Relations Contact:
RedChip Companies, Inc.
Tiziana Life Sciences Ltd
TLSA Rankings
#2682 Ranked by Stock Gains
TLSA Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About TLSA
tiziana life sciences plc is a uk biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. the company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (cdk) involved in cell division as well as a number of other protein kinases. milciclib is currently in phase ii clinical trials for thymic carcinoma in patients previously treated with chemotherapy. the company is also in clinical development of foralumab. foralumab is the only fully human engineered anti-human cd3 antibody in clinical development. this phase ii compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (t1d), inflammatory bowel disease (ibd), psoriasis and rheumatoid arthritis, where modulation of a t-cell response is desirable. tiziana life sciences’ research
